Clinical Trials

45 enrolled 12 charts

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01258933 2025-10-01

Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy

Phase 2 Terminated

4 enrolled 7 charts

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01352312 2025-04-29

Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma

Phase 1 Terminated

10 enrolled

Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT02710643 2022-06-21

FIL_MIRO

110 enrolled

Lymphoma, Lymphoma, Follicular

NCT01190449 2021-08-18

Ofatumumab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma

51 enrolled 7 charts

Lymphoma, Lymphoma, Follicular

NCT01497496 2021-04-27

Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

29 enrolled 9 charts

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01329900 2020-07-08

Chemotherapy Plus Ofatumumab Followed by G-CSF for Mobilization of Peripheral Blood Stem Cells in Patients With Non-Hodgkin's Lymphomas

50 enrolled 7 charts

Lymphoma

NCT01578707 2019-12-18

RESONATE™

Phase 3 Completed

391 enrolled 14 charts

Bronchiolitis Obliterans Syndrome, Leukemia, Lymphoma, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02419469 2018-06-11

Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Phase 2 Terminated

1 enrolled 4 charts

Leukemia, Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00742144 2017-11-17

Ofatumumab in Japanese Patients With CD20 Positive Follicular Lymphoma or Chronic Lymphocytic Leukemia

Phase 1 Completed

6 enrolled

Bronchiolitis Obliterans Syndrome, Leukemia, Lymphoma, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01195766 2016-02-24

Study of Ofatumumab and ESHAP for the Treatment of Hodgkin's Lymphoma

64 enrolled

Hodgkin Disease, Lymphoma

NCT01263418 2015-10-12

Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas

Phase 2 Withdrawn

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Marginal Zone

NCT01131247 2011-07-20

PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & Ofatumumab

Phase 2 Withdrawn

37 enrolled